The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality

Objective We aimed to perform a systematic review and meta-analysis of all-cause and cause-specific mortality of patients with benign endogenous Cushing syndrome (CS). Methods The protocol was registered in PROSPERO (CRD42017067530). PubMed, EMBASE, CINHAL, Web of Science, and Cochrane Central searches were undertaken from inception to January 2021. Outcomes were the standardized mortality ratio (SMR), proportion, and cause of deaths. The I-2 test, subgroup analysis, and meta-regression were used to assess heterogeneity across studies. Results SMR was reported in 14 articles including 3691 patients (13 Cushing disease [CD] and 7 adrenal CS [ACS] cohorts). Overall SMR was 3.0 (95% CI, 2.3-3.9; I-2 = 80.5%) for all CS, 2.8 (95% CI, 2.1-3.7; I-2 = 81.2%) for CD and 3.3 (95% CI, 0.5-6.6; I-2 = 77.9%) for ACS. Proportion of deaths, reported in 87 articles including 19 181 CS patients (53 CD, 24 ACS, and 20 combined CS cohorts), was 0.05 (95% CI, 0.03-0.06) for all CS subtypes with meta-regression analysis revealing no differences between CS subtypes (P = .052). The proportion of deaths was 0.1 (10%) in articles published before 2000 and 0.03 (3%) in 2000 until the last search for CS (P < .001), CD (P < .001), and ACS (P = .01). The causes of death were atherosclerotic diseases and thromboembolism (43.4%), infection (12.7%), malignancy (10.6%), active disease (3.5%), adrenal insufficiency (3.0%), and suicide (2.2%). Despite improved outcomes in recent years, increased mortality from CS persists. The causes of death highlight the need to prevent and manage comorbidities in addition to treating hypercortisolism.

Automated summary

This study conducted a systematic review and meta-analysis on the mortality of patients with benign endogenous Cushing syndrome (CS). The results showed that despite improved outcomes in recent years, there is still an increased mortality from CS. The causes of death mainly include atherosclerotic diseases and thromboembolism, infection, and malignancy.